Cochlear implantation (CI) remains the primary intervention for individuals with severe-to-profound sensorineural hearing loss, and its clinical outcomes can be influenced by the preservation and functional integrity of spiral ganglion neurons (SGNs)....
No actionable change — this is an early-stage in-vitro study; clinical translation to human cochlear implant electrodes requires further animal and then human trials.
If validated in vivo, BDNF-releasing electrode coatings could reduce spiral ganglion neuron degeneration after implantation, potentially improving long-term cochlear implant outcomes.
- 01Electrospinning was used to rapidly fabricate BDNF-releasing coatings on cochlear implant electrode arrays.
- 02The coating sustained BDNF release in vitro, supporting spiral ganglion neuron survival.
- 03Study is in-vitro only — no animal or human data reported.
- 04Technique is described as rapid and reproducible, which may support future scalability.
- 05Targets improvement in outcomes for severe-to-profound sensorineural hearing loss patients.
Electrospun BDNF-releasing coatings sustain BDNF release from cochlear implant electrode arrays in vitro.
studypartially supportedBDNF release from the electrode coating supports spiral ganglion neuron survival in vitro.
studypartially supported- PMID
- 42255601
- DOI
- 10.1021/acsomega.6c00323.
- Journal
- ACS Omega
- Publication type
- research_article
- Evidence level
- 4
- Population
- In vitro cell/tissue model; no human or animal subjects
- Intervention
- Electrospun BDNF-releasing coating applied to cochlear implant electrode arrays
Primary outcomes
BDNF release kinetics from electrospun electrode coating; Spiral ganglion neuron survival in vitro